Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study

British Journal of Dermatology ◽

10.1111/j.1365-2133.2010.09873.x ◽

2010 ◽

Vol 163 (2) ◽

pp. 386-394 ◽

Author(s):

R.-M. Szeimies ◽

P. Radny ◽

M. Sebastian ◽

F. Borrosch ◽

T. Dirschka ◽

...

Keyword(s):

Photodynamic Therapy ◽

Actinic Keratosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/j.yder.2011.02.044 ◽

2011 ◽

Vol 2011 ◽

pp. 369-370

Author(s):

G. Martin

Keyword(s):

Photodynamic Therapy ◽

Actinic Keratosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962498.793465528 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Peritoneal Carcinomatosis ◽

Bowel Obstruction ◽

Symptomatic Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

PIII-38Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.246 ◽

2006 ◽

Vol 79 (2) ◽

pp. P68-P68 ◽

Author(s):

G RICHARDSON ◽

S WANGWEIGAND ◽

S SAINATI ◽

S DEMISSIE

Keyword(s):

Endocrine Function ◽

Phase Iii ◽

Chronic Insomnia ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain

Journal of Pain ◽

10.1016/j.jpain.2009.01.202 ◽

2009 ◽

Vol 10 (4) ◽

pp. S48 ◽

Author(s):

R. Buynak ◽

D. Shapiro ◽

A. Okamoto ◽

C. Lange ◽

M. Etropolski

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Chronic Low Back Pain ◽

Phase Iii ◽

Low Back ◽

Double Blind ◽

Double Blind Placebo ◽

Gastrointestinal Tolerability ◽

Phase Iii Study

Download Full-text

J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx388.064 ◽

2017 ◽

Vol 28 ◽

pp. v564-v565

Author(s):

H. Hashimoto ◽

S. Iwasa ◽

M. Abe ◽

T. Yanai ◽

S. Zenda ◽

...

Keyword(s):

Emetogenic Chemotherapy ◽

Nausea And Vomiting ◽

Antiemetic Therapy ◽

Phase Iii ◽

Highly Emetogenic Chemotherapy ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

The Oncologist ◽

10.1634/theoncologist.2012-0448 ◽

2013 ◽

Vol 18 (3) ◽

pp. 257-264 ◽

Author(s):

Sandra M. Swain ◽

Michael S. Ewer ◽

Javier Cortés ◽

Dino Amadori ◽

David Miles ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

A randomized, double‐blind, phase III , multicentre study to evaluate the safety and efficacy of BF ‐200 ALA (Ameluz ® ) vs. placebo in the field‐directed treatment of mild‐to‐moderate actinic keratosis with photodynamic therapy (PDT) when using the BF ‐Rhodo LED ® lamp

British Journal of Dermatology ◽

10.1111/bjd.14498 ◽

2016 ◽

Vol 175 (4) ◽

pp. 696-705 ◽

Author(s):

U. Reinhold ◽

T. Dirschka ◽

R. Ostendorf ◽

R. Aschoff ◽

C. Berking ◽

...

Keyword(s):

Photodynamic Therapy ◽

Multicentre Study ◽

Actinic Keratosis ◽

Phase Iii ◽

Double Blind ◽

Safety And Efficacy

Download Full-text

Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

10.1158/1538-7445.sabcs18-ct158 ◽

2019 ◽

Author(s):

Shannon N. Westin ◽

Rebecca S. Kristeleit ◽

Robert L. Coleman ◽

Keiichi Fujiwara ◽

Amit M. Oza ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Platinum Based Chemotherapy ◽

Phase Iii Study

Download Full-text